(°¡) ±³Á÷¿ø¸í´Ü
Á÷±Þ ¼º¸í Á÷±Þ ¼º¸í
ÆÀÀå
±èÁø±Ù
ÆÀ¿ø
ÀÌÈ­¼±
ÆÀ¿ø
À±¿¬Á¤
   

(³ª) ÁÖ¿äȰµ¿»çÇ×
1)
ÃÊû°­¿¬È¸
¿¬¹ø ÀϽà °­»ç¸í ¼Ò¼Ó±â°ü °­¿¬Á¦¸ñ
1
2016.5.23
±è¾Æ¶÷
¡¤
°úÇÐÀû ÀÇ»ç¼ÒÅëÀÇ ±¸Á¶
¡°Structure of Scientific Communication¡±
2
2016.6.14
James Yoo
Wake Forest Institute for begenerative Medicine
Recent Advances and Future Perspectives of Regenerative Medicine
3
2016.7.7
³²º´È£
±¹¸³¾Ï¼¾ÅÍ, Herigs ´ëÇ¥
Àӻ󿬱¸¿¡¼­ÀÇ Åë°èÀû °í·Á»çÇ×
4
2016.10.6
Åë°èÀÚ¹® ¹æ¹ý°ú ¼³¸íȸ
5
2016.10.18
¼­Àç¸í
Ä«À̽ºÆ® ÀǰúÇдëÇпø
From feast to famine: Biology and pharmacology of Fibroblast Growth Factor 1
6
2016.11.2
¹ÚµÎÁø
¹ÚµÎÁøÈ¸°è»ç¹«¼Ò
±¹Ã¥°úÁ¦ÀÇ È¸°è°ü¸®
7
2016.12.7
È«¼®ÁØ
´ë±¸½Ã ¹Ì·¡»ê¾÷ÃßÁøº»ºÎ
´ë±¸ ¹Ì·¡»ê¾÷ ÃßÁø¹æÇâ
8
2017.2.24
ÀÌÀαÔ
°æºÏ´ëÇб³
¿¬±¸Á߽ɺ´¿ø ÃßÁø°æÇè - °æºÏ´ëÇб³ ¿¹

2)
±âÃÊ - Àӻ󼼹̳ª
¿¬¹ø ÀϽà °­»ç¸í ¼Ò¼Ó±â°ü
°­¿¬Á¦¸ñ
1
2016.5.26
(Á¦1ȸ)
Á¶È£Âù
³»ºÐºñ³»°ú
³»ºÐºñ³»°úÀÇ ±âÃÊ - ÀÓ»ó ¿¬°è¿¬±¸ »ç·Ê¹ßÇ¥
Àӽ¼ø
»ý¸®Çб³½Ç
Regulatory mechanism of IGFBP-2 by PPARa in metabolic signaling
2
2016.6.30
(Á¦2ȸ)
À̼º·æ
¾à¸®Çб³½Ç
Dual contributions of MMP on the cerebral ischemia
¼­¿µ¼º
°¡Á¤ÀÇÇаú
Èú¸µÇªµå ÇÁ·ÎÁ§Æ®
3
2016.8.18
(Á¦3ȸ)
ÀÌÀ±ÇÑ
ºÐÀÚÀÇÇб³½Ç
º¸°Çº¹Áö°¡Á·ºÎ ÀÓ»óÇöÀå¹ß±¼ ±¹°¡ÇÙ½ÉÁß°³¿¬±¸
¼öÇà»óȲ ¼Ò°³
ÀÌÇü
½Å°æ°ú
What is the meaning of patient in the clincal faculty of medical school?
4
2016.10.18
(Á¦4ȸ)
±ÇÅñÔ
¸é¿ªÇб³½Ç
Cancer cell death : Apoptosis and Non-apoptotic cell death
Çã½ÂÈ£
½ÉÀå³»°ú
Invasive Coronary Imaging
5
2016.12.21
(Á¦5ȸ)
ÇÏÀº¿µ
»ýÈ­Çб³½Ç
Thyroidectomy Stimulates Glucagon-Like Peptide-1 Secretion and Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Fed Rats
·ù½Â¿Ï
À§Àå°ü¿Ü°ú
ºñ¸¸¼ö¼ú¿¡¼­ ±âÃÊ¿¬±¸ÀÇ Çʿ伺
6
2017.1.25
(Á¦6ȸ)
񊫏
¸é¿ªÇб³½Ç
Development of Anti-cancer Drug 1. Multi-target drug, BAI 2. An interesting target, PIM
°­±¸Á¤
°£´ãÃé¿Ü°ú
Delivery of idea from liver surgery to molecule ; ischemia / reperfusion injury and HCC gene expression
7
2017.2.9
(Á¦7ȸ)
·ù¼º¿­
°¨¿°³»°ú
Antibiotic Resistance and Clinical Presentation of healthcare -associate hypervirulent K.pneumoniae infection
±è ½Å
¸é¿ªÇб³½Ç
ÀÓ»ó - ±âÃÊ , ÀÓ»ó - ÀÓ»óÀÇ °øµ¿ /À¶º¹ÇÕ ¿¬±¸ÁÖÁ¦ °³¹ß ¹× °¢Á¾ ¿¬±¸ºñ ½Åû ÁÖÁ¦ °³¹ß
·ù¿µ¿í
ÇǺΰú
¼Õ»óµÈ ÇǺÎÀÇ Àç»ý°úÁ¤¿¡ °ü¿©ÇÏ´Â ÀÎÀÚ¿¡ ´ëÇÑ ¿¬±¸

3)
¿ÜºÎ ¿¬±¸°úÁ¦ ÇöȲ
°¡)
Á¾·á°úÁ¦
¿¬¹ø °úÁ¦¸í ¿¬±¸Ã¥ÀÓÀÚ ÃÑ¿¬±¸±â°£ ÃÑ¿¬±¸ºñ (´ÜÀ§:¿ø)
1
Ç÷·ù·® °¨Áö¼¾¼­°¡ °áÇյǾî
Áö¼ÓÀûÀ¸·Î Ç÷°ü°³ÅëÀ»
¸ð´ÏÅ͸µÇÏ´Â
Ç÷°ü¹®ÇսýºÅÛ °³¹ß
¼ºÇü¿Ü°ú
¼Õ´ë±¸
2014.7.1~
2016.6.30
24°³¿ù
142,000,000
2
ºÎÁ¤¸Æ¿¡ ÀÇÇÑ ³úÁ¹Áß ¿¹¹æ
±³À°¿ë µ¿¿µ»ó Á¦ÀÛ
(1Â÷³âµµ)
½ÉÀå³»°ú
ÇѼº¿í
2015.8.1.~
2016.7.31
12°³¿ù
11,000,000
3
À̽ÄÀΠüÀ°´ëȸ¸¦ Ȱ¿ëÇÑ
Àå±â±âÁõ È«º¸È¿°ú ºÐ¼®
(Korea Transplant Game)
¿Ü°ú
Á¶¿øÇö
2016.9.1.~
2017.2.28
6°³¿ù
10,000,000
4
±Ù·ÎÀڰǰ­¼¾ÅÍÀÇ
¿ªÇÒ ¹× ±â´É µî
°³¼±¹æ¾È¿¡ °üÇÑ ¿¬±¸
Á÷¾÷ȯ°æ
ÀÇÇаú
¾ç¼±Èñ
2016.9.29.~
2016.12.15.
2°³¿ù
38,500,000
5
Èİ¢ ¹ÙÀÌ¿À Á¤º¸ ±â¹Ý
°¨¼ºÁõ°­ ÀÎÅÍ·¢Æ¼ºê
ÄÜÅÙÃ÷ ±â¼ú °³¹ß
¼ÒÈ­±â
³»°ú
À庴±¹
2016.9.1.~
2017.1.31
5°³¿ù
50,000,000
6
Sphingosine-1-
phosphate signaling
Á¶ÀýÀ» ÅëÇÑ TRAIL
ÀúÇ×¼º ±Øº¹ ¹æ¾È¿¬±¸
¸é¿ªÇÐ
¹Î°æÁø
2013.6.1.~
2016.5.31
24°³¿ù
150,930,000
7
º¹°­°æ ¼ö¼ú¿ë
½º¸ðÅ© ÇÊÅͰ³¹ß
»êºÎÀΰú
Á¶Ä¡Èì
2015.10.1.~
2016.5.31
8°³¿ù
8,700,000
8
¸¸¼ºÁúȯ °ü¸®¸¦ À§ÇÑ
ÀÎü»ðÀÔÇü »ý¸®±â´É
ÀÚµ¿°¨½Ã½Ã½ºÅÛ ±â¼ú °³¹ß
½ÉÀå³»°ú
±èÀ±³â
2012.6.1.~
2017.2.28
56°³¿ù
864,900,000

³ª)
ÁøÇà°úÁ¦
¿¬¹ø °úÁ¦¸í ¿¬±¸Ã¥ÀÓÀÚ ÃÑ ¿¬±¸±â°£ ÃÑ¿¬±¸ºñ(´ÜÀ§:¿ø)
1
ÀÚ±â ÁÖµµÇü ÈÞ´ë¿ë
»ýȰȯ°æ ¾ÈÀüÁø´Ü ŰƮ ¾Û
±â¹Ý ¼­ºñ½º ½Ã½ºÅÛ
½ÉÀå³»°ú
±èÀ±³â
2016.5.1.~
2020.4.30
48°³¿ù
700,000,000
2
ºÎÁ¤¸Æ¿¡ ÀÇÇÑ ³úÁ¹Áß ¿¹¹æ
±³À°¿ë µ¿¿µ»ó Á¦ÀÛ
½ÉÀå³»°ú
ÇѼº¿í
2015.8.1.~
2017.7.31
24°³¿ù
22,000,000
3
À¯Ã¼µ¿¿ªÇÐ À¯Ã¼Ä¨À»
ÀÌ¿ëÇÑ Ç÷Á߾ϼ¼Æ÷ ¹×
Ç÷Àå ºÐ¸®¿ë À¶ÇÕÇü
ÀüÇ÷¾× ºÐ¸®¸ðµâ °³¹ß
¼ÒÈ­±â³»°ú
À庴±¹
2015.07.01.~
2017.06.30.
24°³¿ù
60,000,000
4
À¯Ã¼µ¿¿ªÇÐ À¯Ã¼Ä¨ ±â¹Ý
°£¾Ï Áø´Ü±â±â °³¹ß
¼ÒÈ­±â³»°ú
À庴±¹
2016.04.1.~
2019.3.31
36°³¿ù
33,500,000
5
ICT ÀÓ»ó½ÃÇè ½Ã½ºÅÛ
°³¹ß ¹× »ê¾÷È­ ±â¹Ý±¸Ãà
½ÉÀå³»°ú
¹ÚÇü¼·
2015.11.01.~
2018.11.30
37°³¿ù
606,000,000
6
mTORC2 network
Á¦¾î¸¦ ÅëÇÑ ¼¼Æ÷»ç¸ê
switch ÅëÇÕÁ¶Àý ¿¬±¸
¸é¿ªÇÐ
¹Î°æÁø
2016.11.1.~
2019.10.31
36°³¿ù
150,000,000